EVH240920P27500
- 0.10
- 0.000.00%
Evolent Health Newsroom
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $43
JMP Securities analyst Constantine Davides maintains $Evolent Health(EVH.US)$ with a buy rating, and adjusts the target price from $31 to $43.According to TipRanks data, the analyst has a success
Evolent Health Buy Rating Affirmed With Increased Price Target Amid Growth Prospects and M&A Speculation
Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years
Here's Why Evolent Health (EVH) Is on the List of Bottom Securities of Carillon Eagle Small Cap Growth Fund
Express News | Evolent Health Inc : Stephens Raises Target Price to $38 From $32
Evolent Health, Inc. (EVH): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Evolent Health Is Maintained at Buy by Truist Securities
Evolent Health Insider Sold Shares Worth $1,340,790, According to a Recent SEC Filing
Evolent Health(EVH.US) Officer Sells US$5.64 Million in Common Stock
$Evolent Health(EVH.US)$ Officer Blackley Seth sold 187.9K shares of common stock on Aug 22, 2024 at an average price of $30 for a total value of $5.64 million.Source: Announcement What is statement
Evolent Health Dips on Report Elevance Dropped Out of Bidding
Evolent Health's Standardized, Formulaic Pricing Approaches to Help Manage Volatility Going Forward, RBC Says
Evolent Health Price Target Maintained With a $42.00/Share by RBC Capital
RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target
Evolent Health Analyst Ratings
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
RBC Capital analyst Sean Dodge maintains $Evolent Health(EVH.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 43.0% and a
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating
Truist Financial analyst Jailendra Singh maintains $Evolent Health(EVH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of -13.3%
Truist Financial Sticks to Its Buy Rating for Evolent Health (EVH)
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Evolent Health (EVH)
Evolent Health (EVH) Gets a Buy From RBC Capital